These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33841446)

  • 1. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.
    Sinkovits G; Mező B; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Front Immunol; 2021; 12():663187. PubMed ID: 33841446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
    Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes.
    de Nooijer AH; Grondman I; Janssen NAF; Netea MG; Willems L; van de Veerdonk FL; Giamarellos-Bourboulis EJ; Toonen EJM; Joosten LAB;
    J Infect Dis; 2021 Feb; 223(2):214-224. PubMed ID: 33038254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study.
    Charitos P; Heijnen IAFM; Egli A; Bassetti S; Trendelenburg M; Osthoff M
    Front Immunol; 2021; 12():765330. PubMed ID: 34777382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality.
    Defendi F; Leroy C; Epaulard O; Clavarino G; Vilotitch A; Le Marechal M; Jacob MC; Raskovalova T; Pernollet M; Le Gouellec A; Bosson JL; Poignard P; Roustit M; Thielens N; Dumestre-Pérard C; Cesbron JY
    Front Immunol; 2021; 12():742446. PubMed ID: 34567008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.
    Peerschke EI; Valentino A; So RJ; Shulman S; Ravinder
    Front Immunol; 2021; 12():716361. PubMed ID: 34491250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2-infected primary human airway epithelia.
    Posch W; Vosper J; Noureen A; Zaderer V; Witting C; Bertacchi G; Gstir R; Filipek PA; Bonn GK; Huber LA; Bellmann-Weiler R; Lass-Flörl C; Wilflingseder D
    J Allergy Clin Immunol; 2021 Jun; 147(6):2083-2097.e6. PubMed ID: 33852936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality.
    Alosaimi B; Mubarak A; Hamed ME; Almutairi AZ; Alrashed AA; AlJuryyan A; Enani M; Alenzi FQ; Alturaiki W
    Front Immunol; 2021; 12():668725. PubMed ID: 34276659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Complement C3 and C4 and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression.
    Zinellu A; Mangoni AA
    Front Immunol; 2021; 12():696085. PubMed ID: 34163491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement Activation in Kidneys of Patients With COVID-19.
    Pfister F; Vonbrunn E; Ries T; Jäck HM; Überla K; Lochnit G; Sheriff A; Herrmann M; Büttner-Herold M; Amann K; Daniel C
    Front Immunol; 2020; 11():594849. PubMed ID: 33584662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement activation predicts negative outcomes in COVID-19: The experience from Northen Italian patients.
    Meroni PL; Croci S; Lonati PA; Pregnolato F; Spaggiari L; Besutti G; Bonacini M; Ferrigno I; Rossi A; Hetland G; Hollan I; Cugno M; Tedesco F; Borghi MO; Salvarani C
    Autoimmun Rev; 2023 Jan; 22(1):103232. PubMed ID: 36414219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients.
    Barratt-Due A; Pettersen K; Børresdatter-Dahl T; Holter JC; Grønli RH; Dyrhol-Riise AM; Lerum TV; Holten AR; Tonby K; Trøseid M; Skjønsberg OH; Granerud BK; Heggelund L; Kildal AB; Schjalm C; Aaløkken TM; Aukrust P; Ueland T; Mollnes TE; Halvorsen B;
    J Intern Med; 2024 Jul; 296(1):80-92. PubMed ID: 38539241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: A retrospective cohort study.
    Fang S; Wang H; Lu L; Jia Y; Xia Z
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107070. PubMed ID: 33039965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients.
    Lage SL; Rocco JM; Laidlaw E; Rupert A; Galindo F; Kellogg A; Kumar P; Poon R; Wortmann GW; Lisco A; Manion M; Sereti I
    Front Immunol; 2022; 13():815833. PubMed ID: 35250994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Inflammatory Markers with Mortality in COVID-19 Infection.
    Arshad AR; Khan I; Shahzad K; Arshad M; Haider SJ; Aslam MJ
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):158-163. PubMed ID: 33291195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state.
    Henry BM; Szergyuk I; de Oliveira MHS; Lippi G; Benoit JL; Vikse J; Benoit SW
    J Med Virol; 2021 Sep; 93(9):5515-5522. PubMed ID: 33974276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Inflammation and Complement Activation Parameters Predict Clinical Outcome of Severe SARS-CoV-2 Infections.
    Huber S; Massri M; Grasse M; Fleischer V; Kellnerová S; Harpf V; Knabl L; Knabl L; Heiner T; Kummann M; Neurauter M; Rambach G; Speth C; Würzner R
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.
    Leatherdale A; Stukas S; Lei V; West HE; Campbell CJ; Hoiland RL; Cooper J; Wellington CL; Sekhon MS; Pryzdial ELG; Conway EM
    Med Microbiol Immunol; 2022 Feb; 211(1):37-48. PubMed ID: 35034207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.
    Vitiello A; La Porta R; D'Aiuto V; Ferrara F
    Hum Immunol; 2021 Apr; 82(4):264-269. PubMed ID: 33632561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients.
    Prado-Galbarro FJ; Sanchez-Piedra C; Gamiño-Arroyo AE; Cruz-Cruz C
    Public Health; 2020 Dec; 189():66-72. PubMed ID: 33166857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.